Cutler Group LP Tcr2 Therapeutics Inc. Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 Apr 26, 2021	SELL	$20.38 - $34.07 $24,456 - $40,884	-1,200 Reduced 92.31%	100 $0
Q4 2020 Jan 21, 2021	BUY	$19.0 - $32.63 $1,900 - $3,263	100 Added 8.33%	1,300 $2,000
Q3 2020 Oct 27, 2020	SELL	$13.1 - $20.69 $1,310 - $2,069	-100 Reduced 7.69%	1,200 $13,000
Q2 2020 Jul 22, 2020	BUY	$6.51 - $16.85 $3,906 - $10,110	600 Added 85.71%	1,300 $6,000
Q1 2020 May 07, 2020	BUY	$6.01 - $16.01 $4,207 - $11,207	700 New	700 $0

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.